Cannara Biotech has received approval from Health Canada to amend its license to permit the sale of dried cannabis products to provincially authorized distributors and retailers nationwide.
"Within our home province of Quebec, demand for high quality Quebec-grown cannabis is strong and expanding rapidly," said Zohar Krivorot, President and Chief Executive Officer of Cannara. "The receipt of our sales license from Health Canada is a significant milestone in our journey and will enable us to continue executing our plan to generate value for consumers and shareholders. We look forward to getting our brand portfolio into the hands of customers across the province of Quebec over the coming months."
Cannara products
Cannara indoor-grown cannabis is produced to the highest quality standards. As a result, cannabis is cultivated from a bank of rare genetics, hang-dried, slow-cured, and hand-trimmed. The Company plans to initially launch three product lines:
- THC-dominant: Top-shelf genetics featuring hand-crafted cannabis with elevated THC and rich terpene profiles, available in 3.5 gram and pre-roll formats.
- CBD-dominant: Unique genetics containing less THC and more CBD available in 3.5 gram and pre-roll formats.
- High-value: Quality cannabis offered at an accessible price point in a 28 grams bulk format.
Cannara Facility
Cannara's 625,000 square foot indoor facility in Farnham, Quebec is a purpose-built, state of the art cannabis production facility. The fully automated facility has access to 15 megawatts of electricity at some of the lowest rates available anywhere in Canada. The Company has designed its build-out over three initial phases, to grow production in lockstep with revenues and cash flow. It is the largest indoor facility in Quebec, with the ultimate potential to produce up to 100,000 kilos annually at peak capacity.
For more information:
Cannara Biotech
www.cannara.ca